Geneva’s International Chamber Of Commerce Hosts Dialogue Involving Geneva UN Agency and Big Tobacco – For Second Year In A Row 01/10/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher For the second year in a row, Geneva’s International Chamber of Commerce has hosted a dialogue bringing local tobacco industry leaders together with a major Geneva-based UN Agency – in this case to discuss the ‘role of multinationals in economic recovery following the coronavirus’. The ICC’s 6th Business Dialogue, involving Teresa Moreira, Head Competition and […] Continue reading -> World Bank Unleashes US$12 Billion in “Fast-Track” Finance For COVID-19 Vaccine Purchases By Low- And Middle-Income Countries 30/09/2020 Elaine Ruth Fletcher The World Bank will make available up to $12 billion in “fast-track financing” that low- and middle-income countries can access to procure vaccines against Covid-19 – as soon as one is approved, said the Bank’s president David Malpass, on Wednesday. The announcement at a United Nations high-level panel on the pandemic that also included commitments […] Continue reading -> Most Countries Still Have ‘Long Way To Go’ On Tobacco Control In Public Places & Taxation 29/09/2020 Svĕt Lustig Vijay As fresh data reveals that tobacco products kill over 2 million people a year through coronary heart disease, tobacco control advocates are more determined than ever to protect the world against a product that kills half its users, not only from heart attacks but stroke, lung cancer and other diseases as well. Comprehensive, but simple […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Global Aid, Local Choice – Why Calls For Transparency Cut Both Ways 28/09/2020 Ize Adava When donor dollars go missing, the guilty must be held to account. But when past transgressions hold country-ownership of global health programs to ransom with no clear end in sight, everyone loses. Today, almost two million people are living with HIV in Nigeria yet the latest UNAIDS figures show that only about one out of every […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Pharma Reaps Billions Off Orphan Drug Designations, Says New Report By Dutch Investigative Group 30/07/2020 Svĕt Lustig Vijay Big pharma has reaped billions in profit off the back of European orphan drug regulations that are supposed to incentivize R&D for rare diseases, according to an analysis of 120 orphan medicines registered in the EU over the past two decades. Instead of incentivizing R&D for rare maladies, the EU’s orphan drug legislation has turned […] Continue reading -> Italy Publishes National Regulation Requiring Pharma Disclosure Of Public Support For R&D On New Drugs 28/07/2020 Svĕt Lustig Vijay Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading -> Posts navigation Older postsNewer posts
World Bank Unleashes US$12 Billion in “Fast-Track” Finance For COVID-19 Vaccine Purchases By Low- And Middle-Income Countries 30/09/2020 Elaine Ruth Fletcher The World Bank will make available up to $12 billion in “fast-track financing” that low- and middle-income countries can access to procure vaccines against Covid-19 – as soon as one is approved, said the Bank’s president David Malpass, on Wednesday. The announcement at a United Nations high-level panel on the pandemic that also included commitments […] Continue reading -> Most Countries Still Have ‘Long Way To Go’ On Tobacco Control In Public Places & Taxation 29/09/2020 Svĕt Lustig Vijay As fresh data reveals that tobacco products kill over 2 million people a year through coronary heart disease, tobacco control advocates are more determined than ever to protect the world against a product that kills half its users, not only from heart attacks but stroke, lung cancer and other diseases as well. Comprehensive, but simple […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Global Aid, Local Choice – Why Calls For Transparency Cut Both Ways 28/09/2020 Ize Adava When donor dollars go missing, the guilty must be held to account. But when past transgressions hold country-ownership of global health programs to ransom with no clear end in sight, everyone loses. Today, almost two million people are living with HIV in Nigeria yet the latest UNAIDS figures show that only about one out of every […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Pharma Reaps Billions Off Orphan Drug Designations, Says New Report By Dutch Investigative Group 30/07/2020 Svĕt Lustig Vijay Big pharma has reaped billions in profit off the back of European orphan drug regulations that are supposed to incentivize R&D for rare diseases, according to an analysis of 120 orphan medicines registered in the EU over the past two decades. Instead of incentivizing R&D for rare maladies, the EU’s orphan drug legislation has turned […] Continue reading -> Italy Publishes National Regulation Requiring Pharma Disclosure Of Public Support For R&D On New Drugs 28/07/2020 Svĕt Lustig Vijay Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading -> Posts navigation Older postsNewer posts
Most Countries Still Have ‘Long Way To Go’ On Tobacco Control In Public Places & Taxation 29/09/2020 Svĕt Lustig Vijay As fresh data reveals that tobacco products kill over 2 million people a year through coronary heart disease, tobacco control advocates are more determined than ever to protect the world against a product that kills half its users, not only from heart attacks but stroke, lung cancer and other diseases as well. Comprehensive, but simple […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Global Aid, Local Choice – Why Calls For Transparency Cut Both Ways 28/09/2020 Ize Adava When donor dollars go missing, the guilty must be held to account. But when past transgressions hold country-ownership of global health programs to ransom with no clear end in sight, everyone loses. Today, almost two million people are living with HIV in Nigeria yet the latest UNAIDS figures show that only about one out of every […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Pharma Reaps Billions Off Orphan Drug Designations, Says New Report By Dutch Investigative Group 30/07/2020 Svĕt Lustig Vijay Big pharma has reaped billions in profit off the back of European orphan drug regulations that are supposed to incentivize R&D for rare diseases, according to an analysis of 120 orphan medicines registered in the EU over the past two decades. Instead of incentivizing R&D for rare maladies, the EU’s orphan drug legislation has turned […] Continue reading -> Italy Publishes National Regulation Requiring Pharma Disclosure Of Public Support For R&D On New Drugs 28/07/2020 Svĕt Lustig Vijay Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading -> Posts navigation Older postsNewer posts
WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Global Aid, Local Choice – Why Calls For Transparency Cut Both Ways 28/09/2020 Ize Adava When donor dollars go missing, the guilty must be held to account. But when past transgressions hold country-ownership of global health programs to ransom with no clear end in sight, everyone loses. Today, almost two million people are living with HIV in Nigeria yet the latest UNAIDS figures show that only about one out of every […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Pharma Reaps Billions Off Orphan Drug Designations, Says New Report By Dutch Investigative Group 30/07/2020 Svĕt Lustig Vijay Big pharma has reaped billions in profit off the back of European orphan drug regulations that are supposed to incentivize R&D for rare diseases, according to an analysis of 120 orphan medicines registered in the EU over the past two decades. Instead of incentivizing R&D for rare maladies, the EU’s orphan drug legislation has turned […] Continue reading -> Italy Publishes National Regulation Requiring Pharma Disclosure Of Public Support For R&D On New Drugs 28/07/2020 Svĕt Lustig Vijay Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading -> Posts navigation Older postsNewer posts
Global Aid, Local Choice – Why Calls For Transparency Cut Both Ways 28/09/2020 Ize Adava When donor dollars go missing, the guilty must be held to account. But when past transgressions hold country-ownership of global health programs to ransom with no clear end in sight, everyone loses. Today, almost two million people are living with HIV in Nigeria yet the latest UNAIDS figures show that only about one out of every […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Pharma Reaps Billions Off Orphan Drug Designations, Says New Report By Dutch Investigative Group 30/07/2020 Svĕt Lustig Vijay Big pharma has reaped billions in profit off the back of European orphan drug regulations that are supposed to incentivize R&D for rare diseases, according to an analysis of 120 orphan medicines registered in the EU over the past two decades. Instead of incentivizing R&D for rare maladies, the EU’s orphan drug legislation has turned […] Continue reading -> Italy Publishes National Regulation Requiring Pharma Disclosure Of Public Support For R&D On New Drugs 28/07/2020 Svĕt Lustig Vijay Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading -> Posts navigation Older postsNewer posts
Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Pharma Reaps Billions Off Orphan Drug Designations, Says New Report By Dutch Investigative Group 30/07/2020 Svĕt Lustig Vijay Big pharma has reaped billions in profit off the back of European orphan drug regulations that are supposed to incentivize R&D for rare diseases, according to an analysis of 120 orphan medicines registered in the EU over the past two decades. Instead of incentivizing R&D for rare maladies, the EU’s orphan drug legislation has turned […] Continue reading -> Italy Publishes National Regulation Requiring Pharma Disclosure Of Public Support For R&D On New Drugs 28/07/2020 Svĕt Lustig Vijay Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading -> Posts navigation Older postsNewer posts
Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Pharma Reaps Billions Off Orphan Drug Designations, Says New Report By Dutch Investigative Group 30/07/2020 Svĕt Lustig Vijay Big pharma has reaped billions in profit off the back of European orphan drug regulations that are supposed to incentivize R&D for rare diseases, according to an analysis of 120 orphan medicines registered in the EU over the past two decades. Instead of incentivizing R&D for rare maladies, the EU’s orphan drug legislation has turned […] Continue reading -> Italy Publishes National Regulation Requiring Pharma Disclosure Of Public Support For R&D On New Drugs 28/07/2020 Svĕt Lustig Vijay Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading -> Posts navigation Older postsNewer posts
EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Pharma Reaps Billions Off Orphan Drug Designations, Says New Report By Dutch Investigative Group 30/07/2020 Svĕt Lustig Vijay Big pharma has reaped billions in profit off the back of European orphan drug regulations that are supposed to incentivize R&D for rare diseases, according to an analysis of 120 orphan medicines registered in the EU over the past two decades. Instead of incentivizing R&D for rare maladies, the EU’s orphan drug legislation has turned […] Continue reading -> Italy Publishes National Regulation Requiring Pharma Disclosure Of Public Support For R&D On New Drugs 28/07/2020 Svĕt Lustig Vijay Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading -> Posts navigation Older postsNewer posts
Pharma Reaps Billions Off Orphan Drug Designations, Says New Report By Dutch Investigative Group 30/07/2020 Svĕt Lustig Vijay Big pharma has reaped billions in profit off the back of European orphan drug regulations that are supposed to incentivize R&D for rare diseases, according to an analysis of 120 orphan medicines registered in the EU over the past two decades. Instead of incentivizing R&D for rare maladies, the EU’s orphan drug legislation has turned […] Continue reading -> Italy Publishes National Regulation Requiring Pharma Disclosure Of Public Support For R&D On New Drugs 28/07/2020 Svĕt Lustig Vijay Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading -> Posts navigation Older postsNewer posts
Italy Publishes National Regulation Requiring Pharma Disclosure Of Public Support For R&D On New Drugs 28/07/2020 Svĕt Lustig Vijay Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading -> Posts navigation Older postsNewer posts